Vav Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.20 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.20 Cr
as on 24-10-2024
- Company Age 21 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 8.13 Cr
as on 24-10-2024
- Revenue 7.91%
(FY 2023)
- Profit 13.87%
(FY 2023)
- Ebitda 65.34%
(FY 2023)
- Net Worth 7.43%
(FY 2023)
- Total Assets 1.33%
(FY 2023)
About Vav Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 Cr and a paid-up capital of Rs 1.20 Cr.
The company has closed loans amounting to ₹8.13 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Arun Kedia and Sabita Kedia serve as directors at the Company.
- CIN/LLPIN
U24230MH2003PTC138713
- Company No.
138713
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Vav Life Sciences Private Limited offer?
Vav Life Sciences Private Limited offers a wide range of products and services, including Organic and Inorganic Solvents, Organic Chemicals, Pharma Ingredients & Raw Materials, API Intermediate.
Who are the key members and board of directors at Vav Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Kedia  | Director | 16-Jan-2003 | Current |
| Sabita Kedia | Director | 29-Jul-2006 | Current |
Financial Performance of Vav Life Sciences.
Vav Life Sciences Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.91% increase. The company also saw a substantial improvement in profitability, with a 13.87% increase in profit. The company's net worth moved up by a moderate rise of 7.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vav Life Sciences?
In 2023, Vav Life Sciences had a promoter holding of 60.00% and a public holding of 40.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 29 May 2019 | ₹2.65 Cr | Satisfied |
Axis Bank Limited Creation Date: 28 May 2019 | ₹4.00 M | Satisfied |
Bank Of India Creation Date: 08 Dec 2009 | ₹3.20 Cr | Satisfied |
How Many Employees Work at Vav Life Sciences?
Unlock and access historical data on people associated with Vav Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vav Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vav Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
